Skyhawk Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.skyhawktx.com
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Phase 2
Not yet recruiting
- Conditions
- Huntington DiseaseHuntingtons Disease
- Interventions
- Drug: SKY-0515 Placebo
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Skyhawk Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06873334
- Locations
- 🇦🇺
John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺The University of Queensland - Royal Brisbane Womens Hospital, Herston, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath